This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“Cholesterol does not cause heart disease.“ “Cholesterol doesn’t cause heart disease” The argument goes like this. “If cholesterol causes heart disease, why is it that about half of all patients with a heart attack have normal cholesterol? Cholesterol is an essential part of the story.
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
February 1, 2024 — As cardiologists, heart disease patients and the organizations that serve them across the country embark on American Heart Month, DAIC has compiled a snapshot of significant cardiovascular disease (CVD) and stroke statistics, along with a review of the atherosclerosis drug market. per 1,000* - 122.4
Researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease.
Genes influence various biological processes, including cholesterol metabolism, blood pressure regulation, and the strength and structure of your heart and blood vessels. Specific genetic variants, such as those affecting cholesterol metabolism, can increase the likelihood of plaque buildup in the arteries. How Do Genetic Factors Work?
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American College of Cardiology 74th Annual Scientific Session and Expo ( ACC.25 These new data reinforce the use of LODOCO(colchicine, 0.5
We all want to be heart-healthy and ensuring our cholesterol levels are in the normal range is one of the most critical steps. High cholesterol can increase your risk of severe conditions like heart disease and heart attacks. Continue reading to learn four heart-healthy habits that can improve your cholesterol.
3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 1,6 Until recently atherosclerosis has been thought of as the result of passive lipid accumulation in the vessel wall. 4 In the U.S.
The fundamental role of qualitative alterations of lipoproteins in the early development of atherosclerosis has been widely demonstrated. However, the corresponding studies are scarcer in the field of ischemic stroke, despite carotid arteriosclerosis progression underlies at least 20% of ischemic strokes.
Stroke, Volume 54, Issue 12 , Page 3182-3189, December 1, 2023. The identification of a variant in theHDAC9gene as a risk factor for large-artery atherosclerotic stroke, and subsequently coronary artery disease, has opened novel treatment pathways for stroke and more widely atherosclerotic disease.
BackgroundElevated lowdensity lipoprotein cholesterol is a risk factor for atherosclerotic cardiovascular disease, including acute ischemic stroke (AIS), due to large and smallvessel disease. Cholesterol management guidelines recommend lipidlowering therapy (LLT) to prevent atherosclerotic cardiovascular disease events.
Controlling LDL cholesterol. Let's take a 42-year-old male with an LDL cholesterol of 5.1 How much would they benefit from going on a cholesterol lowering medication? Now add in an elevated Lp(a), which is a common genetic cholesterol particle disorder, and that risk reduction gets even bigger. Being active. Not smoking.
Today’s video is on the subject of stroke and in particular cryptogenic strokes. It is therefore crucial to identify the cause of stroke and treat the underlying cause wherever possible. Strokes are characterised by death of brain cells as a result of disruption of blood supply to those cells.
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).
Good cardiovascular health is essential for maintaining a healthy lifestyle and reducing the risk of heart disease, stroke, and other cardiovascular conditions. Maintaining cardiovascular health reduces the risk of developing various heart diseases, including heart attack, stroke, and high blood pressure.
CLEAR Trial of Bempedoic Acid Bempedoic acid is an ATP citrate lyase inhibitor, acting upstream of HMGCoA reductase targeted by statins, and reduces LDL cholesterol levels. There were no significant effects on fatal or nonfatal stroke, death from cardiovascular causes and death from any cause. Nat Commun. 2016 Nov 28;7:13457.
I do apologise for being direct, but this issue is one of the most frequent barriers I encounter to initiating cholesterol-lowering therapy. A therapy that has been proven repeatedly to reduce the probability of heart attacks and strokes in multiple double-blind randomised controlled studies 1. Let’s break this down.
Blood Vessels: Chronic stress can impair the function of the endothelium—the lining of blood vessels—potentially leading to atherosclerosis, a precursor to heart disease. Lipid Metabolism: Chronic stress can alter lipid metabolism, potentially increasing bad cholesterol (LDL) and decreasing good cholesterol (HDL).
(Naturopathic Medicine) According to a subanalysis of a randomised study, low-dose edoxaban (Savaysa) was related with a reduced stroke risk and a negligible increase in bleeding in older Afib patients at high bleeding risk.
Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events. Using a dataset from a different study, the Multi-Ethnic Study of Atherosclerosis , the team validated the accuracy of their model and overall findings.
Stroke, Volume 55, Issue Suppl_1 , Page ATP226-ATP226, February 1, 2024. Background:Lipoprotein a (Lp(a)) is known to be associated with coronary artery disease and carotid artery atherosclerosis.
Stroke, Volume 56, Issue Suppl_1 , Page ADP14-ADP14, February 1, 2025. Background:PCSK9, a key regulator of cholesterol metabolism, has been implicated in atherosclerosis. However, its potential role in vascular cognitive impairment and dementia (VCID) remains elusive.
The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American College of Cardiology 74th Annual Scientific Session and Expo ( ACC.25 These new data reinforce the use of LODOCO(colchicine, 0.5
A CT CAC scan can only identify if there is calcified atherosclerosis, where it is and to what extent. First off, CTCA is a noninvasive test, and many patients with chest pain would previously have needed invasive angiography with all the risks it entails, including heart attack, stroke and death (albeit very rare). And it matters.
If you have high LDL cholesterol and are unsure what that means for your risk of heart disease, this article is for you. Over the course of your lifetime, your LDL cholesterol will slowly increase. By midlife, the average male and female will see a significant rise in their LDL cholesterol. to 4 mmol (135 to 155 mg/dl).
Stroke, Volume 56, Issue Suppl_1 , Page AWP388-AWP388, February 1, 2025. Incident stroke (ischemic and hemorrhagic) was ascertained until the end of 2021 with adjudication by an expert panel. Cox regression was used to estimate the hazard ratio (HR) for incident stroke per doubling of EIC levels, and p-values were FDR corrected.
Lipoprotein (a) Approximately 1 in 5 people have the Lp(a) variant of cholesterol particle that significantly increases the risk of early heart disease and stroke. Blood Pressure Control For every 20 mmHg increase in systolic blood pressure, the risk of dying from heart attack or stroke doubles 3. J Am Coll Cardiol.
Stroke, Volume 55, Issue Suppl_1 , Page AWP239-AWP239, February 1, 2024. Introduction:Apolipoprotein E4 (ApoE4) allele is linked to increased LDL-Cholesterol, one of the main risk factors for intracranial large artery stenosis (ICAS). Whether these interactions influence the risk of stroke and dementia should be further investigated.
Stroke, Volume 55, Issue 2 , Page 269-277, February 1, 2024. BACKGROUND:Sex-specific differences in plaque composition and instability underscore the need to explore circulating markers for better prediction of high-risk plaques.
Another promising advancement is MK-0616 , an oral PCSK9 inhibitor in Phase 3 trials, showing a significant reduction in LDL cholesterol, which provides a more convenient alternative to current injection-based therapies. The trial highlights the importance of reevaluating and optimizing thrombolytic therapies for better patient outcomes.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content